Anti-bacterial mechanism of baicalin-tobramycin combination on carbapenem-resistant Pseudomonas aeruginosa

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

WORD

HTML

1284

Tables (1-5)

315

Sum=1678

Publishing Process of This Article

Item

Count

Browse

162

Download

532

Sum=694

Jun 16, 2023 (publication date) through Feb 21, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Jun 16, 2023; 11(17): 4026-4034
Published online Jun 16, 2023. doi: 10.12998/wjcc.v11.i17.4026

Table 5 Multivariate logistic regression analysis of death group and survival group in Pseudomonas aeruginosa bloodstream infection

Clinical variables	Odds ratio	95%CI	P value
APACHE II	1.27	1.02-1.58	0.033
Albumin < 30 g/L	6.72	1.18-32.57	0.035
Underwent surgery	3.56	1.03-6.22	0.048
The baicalin in combination with tobramycin	0.56	0.42-0.73	0.027

Citation: Jin LM, Shen H, Che XY, Jin Y, Yuan CM, Zhang NH. Anti-bacterial mechanism of baicalin-tobramycin combination on carbapenem-resistant Pseudomonas aeruginosa. World J Clin Cases 2023; 11(17): 4026-4034
URL: https://www.wjgnet.com/2307-8960/full/v11/i17/4026.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i17.4026